ReviewRheumatology international2017
Interstitial lung disease in systemic sclerosis: current and future treatment.
Review in Rheumatology international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 96 citations in OpenAlex.
- Review
- Interstitial lung disease in systemic sclerosis-a retrospective cross-sectional study in Taiwan.Clinical rheumatology · 2026Article
- MMP-7 as a non-invasive biomarker in interstitial lung diseases and other chronic respiratory diseases: a narrative review.Frontiers in medicine · 2026Review
- Increased transient elastography-derived liver stiffness in fibrotic interstitial lung disease compared with healthy controls and its association with high-resolution computed tomography extent: a cross-sectional observational study.Rheumatology international · 2025Observational
- Clinical, radiologic, and serologic predictors of rheumatic disease in interstitial lung disease patients.Clinical rheumatology · 2025Article
- A comparative study of different types of connective tissue-associated interstitial lung disease.BMC medical imaging · 2025Article
- Review
- Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America.International journal of environmental research and public health · 2024Article
- Systemic sclerosis interstitial lung disease: unmet needs and potential solutions.Nature reviews. Rheumatology · 2024Review
- Perioperative Complications in Patients with Systemic Sclerosis: A Comparative Cohort Analysis.Medical research archives · 2023Article
- A randomized clinical trial of bermekimab treatment for clinical improvement of systemic sclerosis.iScience · 2023Article
- The Role of Macrophages in Connective Tissue Disease-Associated Interstitial Lung Disease: Focusing on Molecular Mechanisms and Potential Treatment Strategies.International journal of molecular sciences · 2023Review
- Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis.Journal of inflammation research · 2023Review
- Pirfenidone exacerbates Th2-driven vasculopathy in a mouse model of systemic sclerosis-associated interstitial lung disease.The European respiratory journal · 2022Article
- Scleroderma and interstitial lung disease - A case report.Annals of medicine and surgery (2012) · 2022Article
- Kidney Involvement in Systemic Sclerosis.Journal of personalized medicine · 2022Review
- Animal Models of Systemic Sclerosis: Using Nailfold Capillaroscopy as a Potential Tool to Evaluate Microcirculation and Microangiopathy: A Narrative Review.Life (Basel, Switzerland) · 2022Review
- Immunosuppression use in early systemic sclerosis may be increasing over time.Journal of scleroderma and related disorders · 2022Article
- Variation of usual interstitial pneumonia using HRCT in Scleroderma Patients.Radiology case reports · 2022Article
- Perspective on Fibroblast Activation Protein-Specific PET/CT in Fibrotic Interstitial Lung Diseases: Imaging Fibrosis-A New Paradigm for Molecular Imaging?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and is characterized by vascular damage, inflammation and fibrosis of the skin and various internal organs. Interstitial lung disease (ILD) frequently complicates SSc and can be a debilitating disorder with a poor prognosis. ILD is the most frequent cause of death in SSc, and the management of SSc-ILD patients is a great challenge. Early detection of pulmonary involvement based on a recent decline of lung function tests and on the extent of lung involvement at high-resolution computed tomography is critical for the best management of these patients. This article summarizes classification, pathogenesis, diagnosis, prognosis, survival and finally current and future treatment options in SSc-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.